drugset / Trial / NCT03920215

Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

NCT03920215

Phase 2/3 Completed 101 enrolled Oyster Point Pharma, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of this safety long-term follow-up study was to evaluate the safety of OC-01 Nasal Spray at 6 months and 12 months post treatment in the OPP-002 study (NCT03636061).

Timeline

Start
2018-08-15
Primary completion
2019-09-20
Completion
2019-09-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator Varenicline Small molecule 0.12 mg/ml Intranasal
Comparator Varenicline Small molecule 0.6 mg/ml Intranasal
Comparator Varenicline Small molecule 1.2 mg/ml Intranasal

Indications